3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Completed
2
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
6
Colorectal Neoplasms
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
HER2-positive Colorectal Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Gastrointestinal Stromal Tumors
1
Disease Progression
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Cholangiocarcinoma
1
Interventions
Leucovorin
5
Gemcitabine
5
Fluorouracil
5
Cisplatin
5
durvalumab
3
Oxaliplatin
3
Capecitabine
3
pembrolizumab
2
lenvatinib
2
S 1 (combination)
2
Irinotecan
2
Folfox protocol
2
zimberelimab
1
tocilizumab
1
tislelizumab
1
surufatinib
1
regorafenib
1
pemigatinib
1
neratinib
1
fludarabine
1
donafenib
1
dehydroftorafur
1
Surgical Procedures, Operative
1
Radiotherapy
1
Proton Therapy
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Cholangiocarcinoma
×
regorafenib
×
Clear all
NCT06946849
2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
76 enrolled